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Abstract: The availability of simple SARS-CoV-2 detection methods is crucial to contain the COVID-19
pandemic. This study examined whether a commercial LAMP assay can reliably detect SARS-CoV-2
genomes directly in respiratory samples without having to extract nucleic acids (NA) beforehand.
Nasopharyngeal swabs (NPS, n = 220) were tested by real-time reverse transcription (RT)-PCR and
with the LAMP assay. For RT-PCR, NA were investigated. For LAMP, NA from 26 NPS in viral
transport medium (VTM) were tested. The other 194 NPS were analyzed directly without prior NA
extraction (140 samples in VTM; 54 dry swab samples stirred in phosphate buffered saline). Ten NPS
were tested directly by LAMP using a sous-vide cooking unit. The isothermal assay demonstrated
excellent specificity (100%) but moderate sensitivity (68.8%), with a positive predictive value of 1 and
a negative predictive value of 0.65 for direct testing of NPS in VTM. The use of dry swabs, even
without NA extraction, improved the analytical sensitivity; up to 6% of samples showed signs of
inhibition. LAMP could be performed successfully with a sous-vide cooking unit. This technique is
very fast, requires little laboratory resources, and can replace rapid antigen tests or verify reactive
rapid tests on-site.
Keywords: SARS-CoV-2; COVID-19; RT-PCR; nucleic acids; direct testing; loop-mediated isothermal
amplification; LAMP
1. Introduction
The ongoing pandemic caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is a major challenge for humankind. The virus has infected more than
120 million people worldwide with a death toll of more than 2 million [1]. The impact
of SARS-CoV-2 on healthcare systems and economies is huge. From the beginning of the
pandemic, the demand for rapid, reliable, cheap, and easy-to-use diagnostics has been
great and, even taking into account the progress made, there is still a big gap between
supply and demand. This is especially true in low-resource settings where specialized
equipment and personnel is often lacking [2].
Real-time reverse transcription polymerase chain reaction (RT-PCR) has been con-
sidered the gold standard for the detection of SARS-CoV-2 due to its high specificity and
sensitivity [3]. It is, however, not without drawbacks, as it requires cost-intensive instru-
ments (specialized equipment) and laboratory skills. Additionally, it is time-consuming,
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and the consumables are expensive, making it an unattractive option for low-resource
settings. Furthermore, the reagents and materials required for RT-PCR are often scarce or
unavailable, and as such, development and evaluation of alternative methods are urgently
required [4]. In addition to the now widespread rapid antigen tests, loop-mediated isother-
mal amplification (LAMP) could be a useful alternative. This method can be performed
without the use of thermocyclers and tends to be faster than RT-PCR. Several LAMP assays
for SARS-CoV-2 detection have been developed [4], and a limited number of them have
been evaluated using clinical samples with promising initial results [5–10].
There are various methods for detecting amplified nucleic acids (NA). Probe-based
PCR assays are used most frequently. These require automated detection of the probe
signal but enable specific detection and quantification of the amplificate in real-time during
the run [11]. In contrast, conventional PCRs are rarely used for diagnostic purposes. After
this type of PCR, the amplicon is usually detected by agarose gel electrophoresis based
on its size and with the help of DNA intercalators. This procedure is less sensitive [12]
and requires further evidence of specificity. The colorimetric LAMP enables direct visual
detection of the amplicon by means of color change, which is quick, easy to perform, and
independent of laboratory equipment. The generated amplicon may also be quantified by
spectrophotometry as previously demonstrated [13].
Here we evaluate the performance of a commercially available LAMP assay for the
detection of SARS-CoV-2 in respiratory tract samples compared to RT-PCR. Among other
things, it is investigated to what extent the LAMP method is suitable for the direct detection
of SARS-CoV-2-RNA without prior extraction of NA. Furthermore, the test results are
compared depending on the sampling system used.
2. Materials and Methods
2.1. Loop-Mediated Isothermal Amplification for SARS-CoV-2 Detection
The performance of a research-use-only LAMP assay (SARS-CoV-2 Rapid Colorimetric
LAMP Assay Kit, New England BioLabs, Ipswich, MA, USA) was tested under different
conditions as indicated below. The LAMP reaction was conducted as recommended by
the manufacturer. In brief, 2 µL of NA or 2 µL of the original respiratory material (a swab
in viral transport medium, VTM, or a dry swab stirred in 500 µL of phosphate-buffered
saline, PBS; 20 µL pre-incubated for 10 min at 99 ◦C) were pipetted together with 23 µL of
LAMP reaction mix consisting of 12.5 µL of WarmStart Colorimetric LAMP 2X Master Mix
(containing uracil-DNA glycosylase), 2.5 µL of SARS-CoV-2 LAMP primer mix (targeting
parts of SARS-CoV-2 envelope (E) and nucleoprotein (N) genes), 5.5 µL of nuclease-free
water, and 2.5 µL of guanidine hydrochloride in a 100 µL PCR reaction vessel. Guanidine
hydrochloride has been shown to improve the performance of LAMP [14] and its use is
thus recommended at a concentration of 40 mM. Since our VTM and the PBS did not
contain guanidine hydrochloride, the protocol did not have to be modified. The primer
design for the LAMP assay was described by Zhang et al. [14]. The primer sets used in this
study were provided in the kit and sequence information of these primers is available in the
instruction manual, which is available on the company’s website. The cDNA synthesis and
the isothermal reaction were performed in one step. This is an advantage of the method,
reducing sample handling time and decreasing the contamination risk. For each sample, a
second separate vessel was prepared in order to demonstrate the presence of human NA,
to assess if the reagents are active and used properly and thus demonstrate the absence
of inhibition of reaction. For this purpose, 2.5 µL of the internal control LAMP primer
mix (rActin) was used instead of the SARS-CoV-2 LAMP primer mix. The internal control
LAMP primer mix targets actin RNA at an exon–exon junction, actin being the product of
the human housekeeping gene, ACTB. Upon addition of the patient samples to the internal
control or SARS-CoV-2 test reaction we verified that all starting reactions were pink, as a
color change to yellow or orange at this stage would indicate that the patient samples were
not compatible with the assay. Furthermore, a separate positive control (2 µL of SARS-
CoV-2 positive control) and a non-template control (2 µL of nuclease-free water) were
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included in each experimental setting. The SARS-CoV-2 positive control (N gene) consists
of a plasmid that contains the SARS-CoV-2 N gene (GenBank: MN908947.3). Thereafter,
all vessels were incubated for 30 min at 65 ◦C in a thermocycler (unless otherwise stated)
and immediately placed at room temperature for 5 min followed by recording the color of
the reaction mixture. A yellow color was valued as positive while a pink color was valued
as negative.
2.2. Deep Nasopharyngeal Swab Samples (NPS) Stirred in PBS
We tested 54 dry NPS for the detection of SARS-CoV-2 in the Labor Krause MVZ
GmbH, Kiel, Germany. The swabs were stirred in 500 µL of sterile PBS without calcium
and magnesium (Lonza, Basel, Switzerland) and tested for SARS-CoV-2 RNA using the
LAMP assay and a triplex in-house RT-PCR designed for the detection of the SARS-CoV-
2 N gene RNA as described before [15]. This RT-PCR uses primers and probes for the
simultaneous detection of the SARS-CoV-2 N gene, Pseudomonas phi6 phage, and human
glyceraldehyde-3-phosphate dehydrogenase. In the case of the RT-PCR, NA extraction
was preferentially performed with the KingFisher Flex system and with the ABI7500
real-time thermocycler (both Thermo Fisher Scientific, Waltham, MA, USA) as described
previously [15].
2.3. Deep NPS in VTM with and without NA Extraction for LAMP
We included 140 NPS for the detection of SARS-CoV-2 tested in the Institute for Vi-
rology at the Essen University Hospital. The swab collection kits contained VTM (Yocon
virus sampling kit, Yocon Biology, Beijing, China), which was used for both the PCR and
the LAMP as described above. Detection of the SARS-CoV-2 genomes via RT-PCR was
performed using the RealStar® SARS-CoV-2 RT-PCR kit 1.0 (Altona Diagnostics, Hamburg,
Germany) on a CFX Connect Real-Time PCR detection system (Bio-Rad Laboratories, Her-
cules, CA, USA), and the NA extraction was performed using the MagNA Pure 96 System
(Roche, Mannheim, Germany) according to the manufacturer’s instructions. MagNA Pure
96 System is an automated high-throughput NA isolation system which uses magnetic
glass particle technology. For SARS-CoV-2 diagnostics, we used the viral NA SV Kit; 200 µL
of VTM was pipetted into the MagNA Pure Processing Cartridges and further processed
with the use of a binding/lysis buffer and proteinase K followed by an incubation step.
The elution volume was 100 µL. In the case of 26 additional samples prior to performing
LAMP, instead of heat inactivation, we applied the same NA extraction protocol as for
the RT-PCR: 18 NPS were tested at the Institute for Virology, Essen, using the methods
described above, while 8 NPS were tested at the Institute of Virology, University Hospital
Bonn, after NA extraction (AltoStar AM16, Altona Diagnostics, Hamburg, Germany) with
both LAMP and RT-PCR (Altona Diagnostics, Hamburg, Germany) on a CFX96 Deep Well
Real-Time system.
2.4. Viral Load in Different RT-PCRs Used by the Laboratories
The number of RT-PCR cycles required for the fluorescent signal to exceed the back-
ground level (threshold) was recorded as threshold cycle (Ct). In order to achieve compara-
bility between the results produced by the three laboratories, we tested two SARS-CoV-2
standard samples previously provided by INSTAND e.V. (Düsseldorf, Germany) as well
as dilutions of them. The 104, 105, 106, and 107 SARS-CoV-2 copies/mL corresponded to
Ct values of 31.4, 26.3, 23.1, and 20.2 (E-gene, Altona, Essen), 36.4, 32.8, 29.6, and 26.6 (N
gene, in-house triplex RT-PCR, Kiel) and 29.5, 26.1, 22.9, and 19.3 (E gene, Altona, Bonn),
respectively. Linear regression was performed for both series of values and the viral load
in copies/mL was calculated based on an equation deriving from it.
To evaluate cross-reactivity, samples that tested positive by RT-PCR for endemic
coronaviruses (HCoV NL63, HCoV OC43, HCoV 229E, and HCoV HKU1), influenza A
virus, respiratory syncytial virus, human metapneumovirus, human rhinovirus, or human
bocavirus 1, or several bacterial species (Mycoplasma pneumoniae, Chlamydia pneumoniae,
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Haemophilus influenzae, Bordetella pertussis, Streptococcus pneumoniae, Streptococcus pyogenes,
Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae), were tested using the
LAMP assay. Analyses for the above-mentioned viruses were performed by using the
FTD Respiratory pathogen 21 assay (Fast Track Diagnostics, Mikrogen, Munich, Germany).
Most samples containing viral pathogens were collected before the emergence of SARS-
CoV-2. In the case of sampling from 2020 onwards, SARS-CoV-2 RT-PCR was negative.
The viral samples were present in VTM, or in some cases, only as NA. For the bacterial
samples, 100 µL of a SARS-CoV-2-free NPS stirred in 500 µL of PBS was spiked with a
fresh colony of an ATCC or clinical strain of Haemophilus influenzae, Bordetella pertussis,
Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Escherichia coli and
Klebsiella pneumoniae, respectively. For Mycoplasma pneumoniae and Chlamydia pneumoniae,
10 µL inactivated and resolved external quality assessment samples were spiked into 90 µL
of the NPS. All samples were mixed, heat-inactivated for 10 min at 99 ◦C (except for those
only available as NA) and tested as described by LAMP. Amplification of rActin was noted
as absence of inhibition.
Assessment of test samples for the improvement of diagnostic procedures has been
approved by the ethics committees of the medical faculties of the University of Duisburg-
Essen (20-9512-BO, 13 August 2020) and Kiel University (D467/20, 16 April 2020). Statistical
analysis was performed using SPSS software (v23, SPSS Inc., Chicago, IL, USA), GraphPad
Prism 6.0 (GraphPad, CA, USA), and the platform VassarStats (http://vassarstats.net)
(accessed on 1 March 2021).
3. Results
3.1. Swabs in VTM: Moderate Sensitivity, Good Specificity, Frequent Inhibition
We tested 140 consecutive NPS for the presence of SARS-CoV-2 RNA. The samples
were acquired from the community through the public health department and included
patients with possible/suspected SARS-CoV-2 infections based on clinical and/or epidemi-
ological reasons. The samples were tested with RT-PCR after NA extraction (reference
method) and LAMP after incubation at 99 ◦C for 10 min but without chemical extraction.
Inhibition in LAMP was frequent (13 samples with no evidence of rActin signals, 9.3%)
(Figure 1A). We observed no false positive results but had 25 (19.7%) false negative sam-
ples. True positive results could be observed in 55 (43.3%) samples and true negatives in
47 (37.0%), amounting to a sensitivity of 68.8% (CI 95% 57.3–78.4), a specificity of 100% (CI
95% 90.6–100), a positive predictive value of 1 (CI 95% 0.92–1), and a negative predictive
value of 0.65 (CI 95% 0.53–0.76). A total of 64.7% (n = 55/85) of the samples were correctly
identified as positive, while 5.9% (n = 5/85) of the positive samples showed signs of LAMP
inhibition. The sensitivity of the method improved, when taking into account samples with
an increasingly higher viral load (Figure 1B).
All samples (n = 33) with a viral load over 107 copies/mL, 83.3% (n = 15/18) of the
samples with a viral load between 106 and 107 copies/mL, 50.0% (n = 5/10) of the samples
with a viral load between 105 and 106 copies/mL, and 20.0% (n = 2/10) of the samples
with a viral load between 104 and 105 copies/mL were detectable with LAMP. None of
the nine samples with a viral load less than 104 copies/mL could be detected with LAMP
(Figure 1C).
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Figure 1. Inhibition rate and diagnostic performance of the loop-mediated isothermal amplification reaction (LAMP) assay.
(A) The inhibition rate of the LAMP assay (i.e., failure in detection of rActin) was relatively high in nasopharyngeal swab
samples tested without nucleic acid (NA) extraction. The numbers above the columns indicate the number of inhibited
samples/number of samples tested using the LAMP assay. (B) The sensitivity and specificity of the LAMP assay without
prior NA extraction was compared to RT-PCR after NA extraction (n = 140). Stratification was performed with the inclusion
of all or a fraction of the samples according to their viral load in copies/mL. Inhibited samples were excluded. The sensitivity
of the LAMP assay increased with increasing viral load. The specificity amounted to 100% irrespective of stratification.
The error bars show the 95% confidence intervals. The numbers under the lines indicate the number of samples that tested
positive using the LAMP assay/number of samples that tested positive using RT-PCR, n = number of negative and positive
samples above the respective viral load threshold per RT-PCR. (C) The rate of detection differed amongst the three groups of
samples. Dry swabs without NA extraction outperformed swabs in viral transport medium (VTM) without NA extraction.
Performing NA extraction prior to testing increased the detection rate for samples with low viral loads considerably. The
numbers above the columns indicate the number of samples that tested positive using the LAMP assay/number of samples
that tested positive using RT-PCR.
3.2. Dry Swabs in PBS: Higher Detection Rate in Samples with Low Viral Load Compared to
Swabs in VTM
We tested 54 consecutive NPS for the presence of SARS-CoV-2 RNA. NPS were
collected by dry swab and stirred in PBS as described above. The samples were tested with
both RT-PCR after NA extraction, serving as the reference method, and LAMP after viral
inactivation but without extraction. Three samples were inhibited (5.6%) (Figure 1A). All
four SARS-CoV-2-free samples were correctly identified, while seven (14.9%, n = 7/47) of
the positive samples were misidentified as false negative. Samples with a low viral load in
the RT-PCR were more often undetectable with LAMP than samples with a high viral load.
All samples (n = 23) with a viral load exceeding 107 copies/mL were detectable, and nearly
all samples (85.7%, n = 6/7 and 81.8%, n = 9/11) with a viral load between 106 and 107 and
105 and 106 copies/mL, respectively, were also detectable. The detection rate for samples
with a viral load between 104 and 105 copies/mL fell to 40.0% (n = 2/5), while one sample
with less than 104 copies/mL was undetectable with LAMP (Figure 1C).
Additionally, we tested 18 samples (8 with a SARS-CoV-2 load of over 107 copies/mL,
and 10 negative for SARS-CoV-2) in parallel with a rapid lateral flow antigen test (NADAL®
Viruses 2021, 13, 801 7 of 12
COVID-19 Ag Test, Nal von Minden GmbH, Moers, Germany), with RT-PCR serving as the
reference method. Both methods could correctly identify all samples as positive or negative.
Furthermore, two false positive samples identified by another lateral flow antigen test
(SARS-CoV-2 Rapid Antigen Test, Roche, Mannheim, Germany) were tested negative by
LAMP following the 99 ◦C inactivation protocol.
3.3. Swabs in VTM after NA Extraction: Enhanced Detection Rate for Samples with a Low Viral
Load, No Inhibition
We tested 26 NPS in VTM after NA extraction with both LAMP and RT-PCR. Fifteen
(57.7%) samples tested positive in both methods and four (15.4%) samples tested negative
in both methods. One sample (3.8%) tested positive in the LAMP test but not in the RT-PCR,
while six (23.1%) tested positive in the PCR but not the LAMP. There was no evidence of
LAMP inhibition for these samples (Figure 1A). All samples with a viral load higher than
104 copies/mL and 64.7% (n = 11) of samples with a viral load less than 104 copies/mL
were detectable with LAMP (Figure 1C).
3.4. Sous-Vide and LAMP: A Thermocycler Is Not Required
We tested the performance of the LAMP assay using a commercially available sous-
vide cooking unit for households (Russell Hobbs 25630-56 Sous-Vide, Russel Hobbs,
Failsworth, UK). We used heat-inactivated samples (without NA extraction), including
a total of three negative samples and seven SARS-CoV-2-positive samples. The samples
were also tested using RT-PCR (RealStar® SARS-CoV-2 RT-PCR kit 1.0) after NA extraction
(MagNA Pure, Roche). The SARS-CoV-2 viral load of the positive samples ranged from
105 to 107 copies/mL. The samples were immersed in the unit, which was set at 65 ◦C
for 30 min. During the 30-minute period, the sous-vide cooking unit managed to retain
this temperature plus/minus 1 ◦C. Reaction vessels were placed into a plastic bag during
amplification. All samples were correctly identified as positive or negative with the LAMP
assay (Figure 2).
Figure 2. Loop-mediated isothermal amplification (LAMP) assay without a thermocycler. (A) Comparison of RT-PCR vs.
the LAMP assay performed in a household sous-vide cooking unit. (B) Picture of the sous-vide cooking unit during testing,
and (C) of the samples after completion of the assay.
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3.5. No Crossreactivity with Frequent Respiratory Viruses and Bacteria
Samples positive for endemic coronaviruses (HCoV NL63, HCoV OC43, HCoV 229E,
HCoV HKU1), different influenza A virus types, respiratory syncytial virus, human rhi-
novirus, human metapneumovirus, human bocavirus-1 and nine bacterial species were
tested with LAMP. None of these pathogens were detected by the LAMP assay. The results
of the cross-reactivity evaluation of the viral pathogens are shown in Table 1 in more detail.
Table 1. Results of the loop-mediated isothermal amplification (LAMP) assay performed on respiratory samples positive for
common pathogens.
Pathogen Ct of the RT-PCR(If Available)
Number of Samples
Tested Directly
Number of Samples Tested
after Preparation of NA
Result of the LAMP
for SARS-CoV-2
HCoV HKU1 18.6–28.5 4 - negative
HCoV NL63 18.3–28 4 10 negative
HCoV 229E 17.1–27.8 3 - negative
HCoV OC43 18.6–24.9 2 1 negative
IAV H1N1 18.8–24.3 3 - negative
IAV H3N2 23.2 1 - negative
IAV not typed 19.5–24.7 5 - negative
RSV 18–22.3 12 - negative
RSV + HRV 20.7–23 + 30.1–35 3 - negative
RSV + HBoV1 18.8–20.6 + 35–35 2 - negative
HMPV 15.3–23.6 3 3 negative
HMPV + HRV 24.5 + 20.2 1 - negative
HBoV1 13.1–14.6 2 - negative
Haemophilus
influenzae n.a. 1 - negative
Bordetella pertussis n.a. 1 - negative
Streptococcus
pneumoniae n.a. 1 - negative
Streptococcus
pyogenes n.a. 1 - negative
Staphylococcus aureus n.a. 1 - negative
Escherichia coli n.a. 1 - negative
Klebsiella pneumoniae n.a. 1 - negative
Mycoplasma
pneumoniae n.a. 1 - negative
Chlamydia
pneumoniae n.a. 1 - negative
Ct: Cycle threshold; NA: nucleic acids; RT-PCR: reverse transcription real-time PCR; n.a.: not available; HCoV: human coronavirus; RSV:
respiratory syncytial virus; HBoV1: human bocavirus-1; HMPV: human metapneumovirus; HRV: human rhinovirus; IAV: influenza A virus.
4. Discussion
Improving and expanding our diagnostic capacity in light of the COVID-19 pandemic
is crucial. Several LAMP assays for SARS-CoV-2 detection have been developed [4], and
a limited number of them have been evaluated using clinical samples with promising
initial results [5–10]. A previous study presenting the performance of the LAMP assay
indicated excellent specificity (99.5%) for NPS samples but moderate sensitivity (86%) when
performing NA extraction [5]. Another study evaluating 106 leftover NPS showed that
59% could be correctly identified as SARS-CoV-2-positive by a LAMP assay without NA
extraction, but the percentage went up to 82% when including samples with a viral load
greater than 106 copies/mL [16]. Performing LAMP using QuickExtract® lysates directly
prepared from crude patient respiratory tract swab samples led to the correct identification
as positive of 50 to 64% of the samples, depending on the swab volume [8].
We tested 140 NPS samples in VTM, taken in a community setting through the public
health department from individuals with possible/suspected SARS-CoV-2 infections due
to clinical and/or epidemiological reasons. The LAMP assay carried out with VTM without
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NA preparation demonstrated excellent specificity (100%), but only moderate sensitivity
(69%). Only 64% of the samples were correctly identified as positive, while 6% of the
positive samples were inhibited. The detection rate of the method increased considerably
for samples with a high(er) viral load. These results indicate that without NA extraction,
the LAMP assay cannot compete with the combination of RT-PCR and NA extraction in
terms of analytical sensitivity. However, it can reliably identify individuals with a high
viral load, which is relevant when aiming to reduce transmission in a community setting.
We evaluated different test strategies in terms of both usability and diagnostic per-
formance. Focusing on an NA extraction-free approach, we demonstrated that using dry
swabs suspended in PBS led to a better detection rate for samples with lower viral loads
compared to swabs in VTM. Compared to the PBS (without magnesium and calcium),
VTM contains a number of additives. We suspect that these could interfere with direct
testing of low viral loads. Previous studies have indicated that the addition of denaturizing
agents, such as guanidine thiocyanate in the VTM, does not impact the detection of SARS-
CoV-2 RNA via RT-PCR [17]. Using VTM with denaturizing agents helps maintain RNA
integrity overtime and may decrease the risk of transmission of infectious agents in the
laboratory [17]. The addition of guanidine thiocyanate increases the speed and sensitivity
of LAMP [14] and is thus part of the NEB protocol (see Section 2). The use of denaturizing
agents in VTM also has significant disadvantages. Media containing guanidine thiocyanate
are not compatible with many testing platforms, as they can react with sodium hypochlo-
rite, which is used for decontamination in many laboratories [18]. Furthermore, its use
does not allow for cultures of viral isolates [17], which is a major disadvantage for both
diagnostic (e.g., phenotypic drug resistance) and scientific purposes.
Previous studies have shown that dry swabs are appropriate for the PCR detection of
respiratory viruses, including SARS-CoV-2 [19,20]. This is relevant, since using dry swabs
could lower the cost of the sampling kit and provide an alternative in a setting where
procuring VTM is difficult. Furthermore, viral isolation in cell culture is also successful
with dry swabs stirred in PBS [15]. Unsurprisingly, implementing NA extraction prior to
the performance of LAMP increased the analytical sensitivity of the method considerably
compared to the extraction-free protocols.
The greatest advantage of LAMP compared to RT-PCR is that it can be carried out
quickly. Direct testing of NPS takes around 45 min per sample. Furthermore, isothermal
amplification can be readily implemented without use of specialized laboratory equipment
as demonstrated in our study, making it an attractive option in low-resource settings,
and in the case of RT-PCR reagents not being available. The LAMP assay is also scalable,
allowing for the testing of a small number of samples up to high-throughput using 96-well
thermoblocks. A disadvantage of the method is its limited analytical sensitivity when
foregoing NA extraction. As shown above, performing NA extraction can significantly
improve the performance of the method. In most laboratories, NA extraction is performed
using (semi)-automated methods, which require specialized and expensive equipment.
Manual extraction using column-based kits is time-consuming and requires centrifuges,
making it unsuitable for POCT diagnostics. Thus, alternative NA extraction methods that
are fast, reliable, and can be applied in the field may be an option for the improvement of
the performance of LAMP. These include a 30 min silica coated magnetic bead NA method,
which can be performed without the use of any electrical equipment [21], or the use of lysis
and sample inactivation buffers such as QuickExtract (Lucigen) [8,22].
On-site testing with rapid SARS-CoV-2 antigen tests is assigned an important role in
combating the COVID-19 pandemic. The greatest advantage of this kind of point-of-care
(POCT) tests is their ease of use and the extremely short time span of 15 to 20 min until
the test result is available. However, their performance varies markedly [9,23,24] and test
sensitivities depend on the viral load, the time-point of sampling, and the presence of
symptoms [23,25,26]. Importantly, although many POCTs demonstrate high specificity,
false positive results have been reported [23,25,27]. Thus, positive POCT results should be
confirmed by RT-PCT [28]. The analytical sensitivity and specificity of the LAMP assay is
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likely to be superior when compared with different POCTs [15,25,27], and largely meets
the requirements of the World Health Organization [29], especially when using dry swabs.
Because of these advantages, LAMP could replace rapid tests. If fast testing is in the
foreground, it would alternatively be conceivable to use LAMP for on-site confirmation of
reactive rapid tests. To do this, however, another NPS would have to be taken.
A strength of our study is the comprehensive evaluation of the LAMP assay for
the detection of SARS-CoV-2 RNA under different conditions. Yet, our study also has
limitations. Sampling was performed through different healthcare professionals, and as a
result, a standardization beyond following the instructions given by the health authorities
was not possible. Furthermore, the samples were tested in three laboratories using different
RT-PCR assays. A comparison of the results with one another was made possible by
using nationally available standard samples. Nevertheless, we believe that our results
are relevant as they reflect the everyday testing routine and can be of use to the scientific
community. The demand for SARS-CoV-2 diagnostics remains unabated and bottlenecks in
resources are frequent. Expanding the diagnostic capacity and diversifying the diagnostic
methods to fit different circumstances, for example, low-resource settings, seems prudent.
In conclusion, the LAMP assay demonstrated excellent specificity, but moderate
sensitivity compared to RT-PCR. The isothermal amplification method can be implemented
without the use of specialized laboratory equipment and may be useful for the replacement
of POCTs or the immediate confirmation of reactive antigen tests.
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